The numbers INCY said it expected, in its earnings releases of the last 3 years, next to what it then reported for the same period. Each target links to the sentence in the release; each result to the 10-Q or 10-K it was first reported in.
Of 1 range targets with a reported result: 1 came in above the last range given, 0 within it, 0 below it.
| Target | What the company said | Reported | Result |
|---|---|---|---|
| Revenue Fiscal 2026 |
Given $4.77B to $4.94B release 2026-02-10
Raised $5.13B to $5.26B release 2026-07-28
Lowered $1.10B to $1.12B release 2026-10-29
|
– | Not reported yet |
The company's wordsProvides full year 2026 total net product revenue guidance range of $4.77 - $4.94 billion release 2026-02-10 Incyte is raising its full year 2026 total net sales guidance to $5,130 - $5,260 million, reflecting the impact of the agreement with CMS related to the Opzelura line extension, * as well as the continued strong performance of its Hematology and Oncology growth products, including Niktimvo, Monjuvi/Minjuvi and Zynyz. release 2026-07-28 Incyte is raising its full year 2026 net sales guidance for Opzelura to $1,100 - $1,120 million, Hematology and Oncology to $890 - $910 million and total net sales to $5,210 - $5,300 million to reflect continued strong performance across the portfolio. release 2026-10-29 | |||
| Revenue Fiscal 2025 (ended 2025-12-31) |
Given $1.20B release 2025-02-10
Raised $2.95B to $3.00B release 2025-04-29
Raised $3.00B to $3.05B release 2025-07-29
Raised $4.23B to $4.32B release 2025-10-28
|
$5.14B 10-K filed 2026-02-10 |
Above the range |
The company's wordsProvides 2025 Financial Guidance and Highlights 2025 R&D Milestones – Total revenues of $1.2 billion (+ 16% Y/Y) in the fourth quarter 2024 and $4.2 billion (+15% Y/Y) for the full year 2024 release 2025-02-10 – Jakafi ® (ruxolitinib) net product revenues of $709 million in Q1'25 (+24% Y/Y); increasing full year 2025 Jakafi guidance to a new range of $2,950 - $3,000 million from $2,925 - $2,975 million release 2025-04-29 – Jakafi ® (ruxolitinib) net product revenues of $764 million in Q2'25 (+8% Y/Y); raising full year 2025 guidance to a new range of $3,000 - $3,050 million [previously $2,950 - $3,000 million] release 2025-07-29 Raises 2025 full year net product revenue guidance to $4.23 - $4.32 billion release 2025-10-28 | |||
1 target far from the company's reported total, so not compared (usually a target for one product, segment or definition)
- Revenue, Fiscal 2024 (ended 2024-12-31): said $2.74B to $2.77B, reported $4.24B. The company's words
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-13), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Work on INCY in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/INCY/export.csv") into a cell.